Because delayed CINV shouldn’t
Indication: VARUBI® (rolapitant), in combination with other antiemetic agents, is indicated in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Contraindication: VARUBI is contraindicated in patients receiving thioridazine, a CYP2D6 substrate. A significant increase in plasma concentrations of thioridazine may result in QT prolongation and Torsades de Pointes.
CINV, chemotherapy-induced nausea and vomiting.
Despite antiemetic treatment,
More than half are still suffering1
The majority of patients undergoing highly or moderately emetogenic chemotherapy (HEC or MEC) experience delayed chemotherapy-induced nausea and vomiting (CINV)—even when prescribed a
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis recognizes
The need for prevention of delayed CINV2
VARUBI® (rolapitant) as part of an antiemetic regimen:
Proven protection with one dose3
Interaction with CYP2D6 substrates with a narrow therapeutic index